Dataset Information
Optimal nonvitamin K antagonist oral anticoagulant therapy in a warfarin-sensitive patient after left atrial appendage closure: A case report.
Ontology highlight
ABSTRACT: Rationale
Developing an optimal medication strategy poses a challenging task in fragile patients after left atrial appendage closure (LAAC). We report an optimal nonvitamin K antagonist oral anticoagulant (NOAC) therapy in a warfarin-sensitive patient after LAAC.Patient concerns
A 77-year-old nonvalvular atrial fibrillation (NVAF) male carrying 2 warfarin-sensitive alleles experienced 2 gum-bleeding with the international normalized ratio (INR) around 3.Diagnoses
Persistent NVAF with a history of subtotal gastrectomy and moderate renal insufficiency.Interventions
Warfarin was discontinued and vitamin K1 was immediately administrated via intravenous infusion. LAAC was regarded as a preferable option, and rivaroxaban 15 mg daily was managed after LACC.Outcomes
Complete endothelialization on the surface of device was detected via transoesophageal echocardiography (TEE), and no peridevice spillage and adverse event occurred.Lessons
A post-LAAC treatment with NOAC may be a viable regimen in patients intolerant to warfarin.
SUBMITTER: Shen L
PROVIDER: S-EPMC6392999 | biostudies-literature | 2018 May
REPOSITORIES: biostudies-literature
Publications
Optimal nonvitamin K antagonist oral anticoagulant therapy in a warfarin-sensitive patient after left atrial appendage closure: A case report.
Medicine 20180501 18
<h4>Rationale</h4>Developing an optimal medication strategy poses a challenging task in fragile patients after left atrial appendage closure (LAAC). We report an optimal nonvitamin K antagonist oral anticoagulant (NOAC) therapy in a warfarin-sensitive patient after LAAC.<h4>Patient concerns</h4>A 77-year-old nonvalvular atrial fibrillation (NVAF) male carrying 2 warfarin-sensitive alleles experienced 2 gum-bleeding with the international normalized ratio (INR) around 3.<h4>Diagnoses</h4>Persiste ...[more]